EMERGENT BIOSOLUTIONS INC. Deferred Costs, Current
EMERGENT BIOSOLUTIONS INC. (EBS) had Deferred Costs, Current of $41.30 million as of 2021-03-31, per its 10-Q filed 2021-04-30.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredCostsCurrent · last filed 2021-04-30
- 2021-03-31: Deferred Costs, Current $41.30M.
- 2020-12-31: Deferred Costs, Current $41.10M.
- 2020-09-30: Deferred Costs, Current $40.80M.
- 2020-06-30: Deferred Costs, Current $40.60M.
| Period end | Deferred Costs, Current |
|---|---|
| 2021-03-31 | $41.30M 10-Q · filed 2021-04-30 |
| 2020-12-31 | $41.10M 10-Q · filed 2021-04-30 |
| 2020-09-30 | $40.80M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $40.60M 10-Q · filed 2020-07-31 |
| 2020-03-31 | $36.30M 10-Q · filed 2020-05-01 |
| 2019-12-31 | $34.00M 10-K · filed 2021-02-19 |
| 2019-09-30 | $27.30M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $26.50M 10-Q · filed 2019-08-02 |
| 2019-03-31 | $1.30M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $1.20M 10-K · filed 2020-02-25 |
| 2018-09-30 | $4.00M 10-Q · filed 2018-11-02 |
| 2018-06-30 | $3.40M 10-Q · filed 2018-08-03 |
| 2018-03-31 | $3.30M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $2.90M 10-K · filed 2019-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |